Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 6/20 | 0.38 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 4/20 | 0.37 |
| ▸ | BCR | P11274 | 4/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.36 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 2/20 | 0.35 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 2/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.34 |
| ▸ | MGLL | Q99685 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695213 | 0.89 | SLC6A7 (0.41) | SLC6A7GHSRABL1BCRCD274 | |
| SCHEMBL20695434 | 0.82 | FASN (0.43) | ABL1BCRCD274PDCD1LG2MGLL | |
| SCHEMBL20695136 | 0.81 | KIF11 (0.48) | ABL1BCRMGLL | |
| SCHEMBL20695385 | 0.81 | AR (0.38) | GRIN2BABL1BCRMGLL | |
| SCHEMBL20695461 | 0.80 | TTR (0.44) | ABL1BCRCD274PDCD1LG2MGLL | |
| SCHEMBL20695169 | 0.80 | MEN1 (0.47) | SLC6A7EPHX2MGLL | |
| SCHEMBL20695404 | 0.80 | FFAR4 (0.42) | MGLL | |
| SCHEMBL20695358 | 0.79 | CD274 (0.40) | SLC6A7GHSRABL1BCRCD274 | |
| SCHEMBL20695147 | 0.78 | FASN (0.42) | ABL1BCRMGLL | |
| SCHEMBL20695210 | 0.78 | MAPK1 (0.50) | SLC6A7GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10610520-B2 | Heterocyclic compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-05-02 | — | — | US | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
| EP-3438109-A1 | HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2019-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190125728-A1 | HETEROCYCLIC COMPOUND | MAG, HTT, ACHE | SLC6A7 2433/4885GRIN2B 32/4885GRIN1 17/4885 |
| US-10610520-B2 | Heterocyclic compound | MAG, HTT, ACHE | SLC6A7 2433/4885GRIN2B 32/4885GRIN1 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.